Literature DB >> 9261125

Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.

U Persson1, S Souchelnytskyi, P Franzén, K Miyazono, P ten Dijke, C H Heldin.   

Abstract

Members of the transforming growth factor-beta (TGF-beta) superfamily signal via different heteromeric complexes of two sequentially acting serine/threonine kinase receptors, i.e. type I and type II receptors. We generated two different chimeric TGF-beta superfamily receptors, i.e. TbetaR-I/BMPR-IB, containing the extracellular domain of TGF-beta type I receptor (TbetaR-I) and the intracellular domain of bone morphogenetic protein type IB receptor (BMPR-IB), and TbetaR-II/ActR-IIB, containing the extracellular domain of TGF-beta type II receptor (TbetaR-II) and the intracellular domain of activin type IIB receptor (ActR-IIB). In the presence of TGF-beta1, TbetaR-I/BMPR-IB and TbetaR-II/ActR-IIB formed heteromeric complexes with wild-type TbetaR-II and TbetaR-I, respectively, upon stable transfection in mink lung epithelial cell lines. We show that TbetaR-II/ActR-IIB restored the responsiveness upon transfection in mutant cell lines lacking functional TbetaR-II with respect to TGF-beta-mediated activation of a transcriptional signal, extracellular matrix formation, growth inhibition, and Smad phosphorylation. Moreover, TbetaR-I/BMPR-IB and TbetaR-II/ActR-IIB formed a functional complex in response to TGF-beta and induced phosphorylation of Smad1. However, complex formation is not enough for signal propagation, which is shown by the inability of TbetaR-I/BMPR-IB to restore responsiveness to TGF-beta in cell lines deficient in functional TbetaR-I. The fact that the TGF-beta1-induced complex between TbetaR-II/ActR-IIB and TbetaR-I stimulated endogenous Smad2 phosphorylation, a TGF-beta-like response, is in agreement with the current model for receptor activation in which the type I receptor determines signal specificity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261125     DOI: 10.1074/jbc.272.34.21187

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  LC-mass spectrometry analysis of N- and C-terminal boundary sequences of polypeptide fragments by limited proteolysis.

Authors:  Justin G Stroh; Pat Loulakis; Anthony J Lanzetti; Julie Xie
Journal:  J Am Soc Mass Spectrom       Date:  2005-01       Impact factor: 3.109

2.  Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1).

Authors:  Berit Bernert; Helena Porsch; Paraskevi Heldin
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

3.  Functional redundancy of type II BMP receptor and type IIB activin receptor in BMP2-induced osteoblast differentiation.

Authors:  Hongbin Liu; Rongrong Zhang; Di Chen; Babatunde O Oyajobi; Ming Zhao
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

4.  The bone morphogenetic protein type Ib receptor is a major mediator of glial differentiation and cell survival in adult hippocampal progenitor cell culture.

Authors:  A Brederlau; R Faigle; M Elmi; A Zarebski; S Sjöberg; M Fujii; K Miyazono; K Funa
Journal:  Mol Biol Cell       Date:  2004-06-11       Impact factor: 4.138

5.  BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β(3) expression.

Authors:  Hildegonda P H Naber; Eliza Wiercinska; Evangelia Pardali; Theo van Laar; Ella Nirmala; Anders Sundqvist; Hans van Dam; Geertje van der Horst; Gabri van der Pluijm; Bertrand Heckmann; Erik H J Danen; Peter Ten Dijke
Journal:  Cell Oncol (Dordr)       Date:  2011-09-21       Impact factor: 6.730

6.  Neutrophilic Lung Inflammation Suppressed by Picroside II Is Associated with TGF-β Signaling.

Authors:  Soohwan Noh; Kyung-Seop Ahn; Sei-Ryang Oh; Kyun Ha Kim; Myungsoo Joo
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-05       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.